1.95Open1.95Pre Close0 Volume96 Open Interest165.00Strike Price0.00Turnover139.65%IV30.40%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.95Extrinsic Value100Contract SizeAmericanOptions Type-0.0667Delta0.0022Gamma120.14Leverage Ratio-0.3079Theta-0.0055Rho-8.01Eff Leverage0.0556Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet